To further determine whether promoter methylation directly mediates ZMYND10 silencing, we tested whether ZMYND10 expression can be restored by pharmacological demethylation in ZMYND10-downregulated breast cancer cell lines MDA-MB231 and SK-BR-3 via treating with the DNA methyltransferase inhibitor Aza and histone deacetylase inhibitor TSA. This evidence concerns the gene ZMYND10 and breast carcinoma.